This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2024
Title: Jenny H Xie: Innovator in Autoimmune Disease Treatment
Introduction
Jenny H Xie is a prominent inventor based in Princeton, NJ (US). She has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. With a total of 2 patents, her work focuses on innovative methods that aim to improve patient outcomes.
Latest Patents
Jenny H Xie's latest patents include groundbreaking methods for treating systemic lupus erythematosus using a domain antibody directed against CD28. These methods provide a novel approach to treating autoimmune diseases by utilizing domain antibodies that specifically bind to human CD28. The administration cycle may consist of one dose of the domain antibody, which has been shown to reduce symptoms of systemic lupus erythematosus compared to placebo.
Career Highlights
Jenny is currently associated with Bristol-Myers Squibb Company, where she continues to advance her research and development efforts. Her work has garnered attention for its potential to transform treatment protocols for patients suffering from autoimmune conditions.
Collaborations
Some of her notable coworkers include Xavier Valencia and John P Throup, who contribute to her innovative projects and research initiatives.
Conclusion
Jenny H Xie's contributions to the field of autoimmune disease treatment highlight her role as a leading inventor in medical innovation. Her patents and ongoing work at Bristol-Myers Squibb Company reflect her commitment to improving healthcare outcomes for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
